TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9200377

Group type: EXPERIMENTAL
Intervention: Dual regimen (omeprazole 0.6 mg/kg twice a day + amoxicillin 30 mg/kg twice a day)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Triple regimen (dual regimen + clarithromycin 15 mg/kg twice a day)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Successful H pylori eradication
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Active ulcers treatment
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Side effects
Number of subjects: 22
Study: 8477407

Group type: EXPERIMENTAL
Intervention: apomorphine injection (first and second injections)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: apomorphine injection (second injection administered 10 or 80 min after first)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: apomorphine injection (second administration)
Number of subjects: 10
Study: 3630589

Group type: EXPERIMENTAL
Intervention: 0.3 mg kg‐1 diazepam orally with 100 ml of water 2 h before surgery (Group 100)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.3 mg kg‐1 diazepam with 50 ml of water 2 h before surgery (Group 50)
Number of subjects: 40
Study: 30519803

Group type: EXPERIMENTAL
Intervention: Housing First (HF) intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interventions aimed at preventing chronic homelessness, strengthening social networks and community involvement, and providing case management services
Number of subjects: 0
Study: 28431849

Group type: EXPERIMENTAL
Intervention: 0.5% improved hydrogen peroxide (IHP) disinfectant
Number of subjects: 4

Group type: COMPARATOR
Intervention: Quaternary ammonium-based (Quat) disinfectant
Number of subjects: 4
Study: 25851421

Group type: EXPERIMENTAL
Intervention: HG broccoli diet (400 g per week for 12 weeks)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Standard broccoli diet (400 g per week for 12 weeks)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Combined data from both studies for HG broccoli
Number of subjects: 130
Study: 23689176

Group type: EXPERIMENTAL
Intervention: Cervilenz® cervicometer
Number of subjects: 50

Group type: COMPARATOR
Intervention: Transvaginal ultrasound
Number of subjects: 50
Study: 21114369

Group type: EXPERIMENTAL
Intervention: Sildenafil (40 mg oral dose)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Prostaglandin E1 (PGE1, alprostadil 200 ng · kg(‐1) · min(‐1) intravenous infusion)
Number of subjects: 13
Study: 19683591

Group type: EXPERIMENTAL
Intervention: SFC+LTRA (pranlukast 450 mg daily)
Number of subjects: 32

Group type: COMPARATOR
Intervention: SFC therapy alone
Number of subjects: 32
Study: 16934430

Group type: EXPERIMENTAL
Intervention: Ceftazidime
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Imipenem/cilastatin
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Cefoperazone/sulbactam
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 22
Study: 15223852

Group type: EXPERIMENTAL
Intervention: 250 mg flutamide once daily
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 250 mg flutamide twice daily
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 250 mg flutamide 3 times daily
Number of subjects: 50

Group type: COMPARATOR
Intervention: Flutamide at 500 mg daily
Number of subjects: 50
Study: 11422007

Group type: EXPERIMENTAL
Intervention: Quinapril 20 mg single dose
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Quinaprilat
Number of subjects: 6
Study: 9639751

Group type: EXPERIMENTAL
Intervention: 0.025 mg ethinyl estradiol (EE)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 0.05 mg ethinyl estradiol (EE)
Number of subjects: 19
Study: 8481662

Group type: EXPERIMENTAL
Intervention: High-dose cytosine arabinoside (3.0 g/m2 for < 60 years; 1.0 g/m2 for older pts.) combined with mitoxantrone (10 mg/m2/d)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Intermediate dose cytosine arabinoside (1.0 g/m2 for < 60 years; 0.5 g/m2 for older pts.) combined with mitoxantrone (10 mg/m2/d)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: High-dose cytosine arabinoside
Number of subjects: 193

Group type: COMPARATOR
Intervention: Intermediate dose cytosine arabinoside
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 193
Study: 3318444

Group type: EXPERIMENTAL
Intervention: S-adenosylmethionine (SAMe) 1,200 mg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Indomethacin 150 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: S-adenosylmethionine (SAMe)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 36
Study: 31619350

Group type: EXPERIMENTAL
Intervention: Vibration therapy (VT)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (no vibration therapy)
Number of subjects: 14
Study: 30033595

Group type: EXPERIMENTAL
Intervention: Anakinra 100 mg once or twice daily
Number of subjects: 99

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 99
Study: 26869246

Group type: COMPARATOR
Intervention: Pharmacotherapy
Number of subjects: 1700

Group type: COMPARATOR
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 1700
Study: 24598243

Group type: EXPERIMENTAL
Intervention: GLP-1 (1.2 pmol/kg/min)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 23072079

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (conventional acupuncture at Tianshu, Zusanli, Shangjuxu, Sanyinjiao, Taichong with electric stimulation at bilateral Tianshu), 3-4 treatments per week for 4 weeks.
Number of subjects: 70

Group type: COMPARATOR
Intervention: Western medication (Pinaverium, 50 mg orally, 3 times a day for 4 weeks).
Number of subjects: 70
Study: 20589921

Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Reboxetine (4 mg)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 18408565

Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Pitavastatin (4 mg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: SLCO1B1*15 variant
Number of subjects: 11
Study: 16088834

Group type: EXPERIMENTAL
Intervention: 3 days of artesunate-atovaquone-proguanil (AAP)
Number of subjects: 81

Group type: COMPARATOR
Intervention: 7 days of supervised quinine (SQ7)
Number of subjects: 81
Study: 11115818

Group type: EXPERIMENTAL
Intervention: Duodenal infusion of lipid
Number of subjects: 29

Group type: COMPARATOR
Intervention: Duodenal infusion of saline
Number of subjects: 29
Study: 9695140

Group type: EXPERIMENTAL
Intervention: Naloxone (1.0 mg/kg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline solution (control)
Number of subjects: 10
Study: 7981009

Group type: EXPERIMENTAL
Intervention: Nadolol 5 mg (N5)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Nadolol 20 mg (N20)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Nadolol 80 mg (N80)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 8
Study: 2723129

Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 3

Group type: COMPARATOR
Intervention: Methylphenidate
Number of subjects: 3

Group type: COMPARATOR
Intervention: Fenfluramine
Number of subjects: 3
Study: 29386337

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT) as an add-on to standard PR programme
Number of subjects: 84

Group type: COMPARATOR
Intervention: Standard PR programme alone
Number of subjects: 84
Study: 27356696

Group type: EXPERIMENTAL
Intervention: Health education programs for teachers and support for tobacco control policy implementation
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control condition (no intervention)
Number of subjects: 72
Study: 24937652

Group type: EXPERIMENTAL
Intervention: Watch video group (43 patients, 43 eyes)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Orally taught health education group (43 patients, 43 eyes)
Number of subjects: 86
Study: 23106948

Group type: EXPERIMENTAL
Intervention: sorafenib or sunitinib
Number of subjects: 124

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 124
Study: 20920812

Group type: EXPERIMENTAL
Intervention: Variable Priority Training (VPT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Full Emphasis Training (FET)
Number of subjects: 0
Study: 18410636

Group type: EXPERIMENTAL
Intervention: Tetanus toxoid booster (TTB) immunization, administered to 52 participants (15 from PI-sparing, 37 from PI-containing) at median 25 weeks after HAART initiation.
Number of subjects: 75

Group type: COMPARATOR
Intervention: No TTB immunization, administered to 23 participants (6 from PI-sparing, 17 from PI-containing).
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: PI-sparing regimen, 21 participants.
Number of subjects: 75

Group type: COMPARATOR
Intervention: PI-containing regimen, 54 participants.
Number of subjects: 75
Study: 15813871

Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 15

Group type: COMPARATOR
Intervention: Prone position
Number of subjects: 15
Study: 12204508

Group type: EXPERIMENTAL
Intervention: felodipine (5 mg)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: metoprolol (50 mg)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: enalapril (10 mg)
Number of subjects: 145

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: clinically prescribed medications
Number of subjects: 145
Study: 11151867

Group type: EXPERIMENTAL
Intervention: Esomeprazole (40 mg once daily), amoxicillin (1 g b.i.d.), and clarithromycin (500 mg b.i.d.) (EAC)
Number of subjects: 612

Group type: COMPARATOR
Intervention: Esomeprazole (40 mg once daily), clarithromycin (500 mg twice daily) (EC)
Number of subjects: 612

Group type: COMPARATOR
Intervention: Esomeprazole (40 mg once daily) (E)
Number of subjects: 612

Group type: EXPERIMENTAL
Intervention: Baseline clarithromycin resistance
Number of subjects: 612

Group type: EXPERIMENTAL
Intervention: Emergent resistance after treatment with EAC
Number of subjects: 612
Study: 8807099

Group type: EXPERIMENTAL
Intervention: Continuous infusion GM‐CSF (GM‐CSF (CI))
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuous infusion GM‐CSF followed by sequential G‐CSF (GM‐CSF/G‐CSF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Historical control patients receiving GM‐CSF as a 2‐h intravenous infusion (GM‐CSF (2‐h))
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuous infusion GM‐CSF (GM‐CSF (CI)) and GM‐CSF/G‐CSF
Number of subjects: 0
Study: 1581405

Group type: EXPERIMENTAL
Intervention: rhGM-CSF at a daily dose of 108 micrograms (group I)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: rhGM-CSF at a daily dose of 216 micrograms (group II)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Cytogenetic analysis
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Overall response to GM-CSF
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Completion of treatment
Number of subjects: 82
Study: 3970886

Group type: EXPERIMENTAL
Intervention: Steamed flax dust
Number of subjects: 12

Group type: COMPARATOR
Intervention: Untreated flax dust
Number of subjects: 12
Study: 31152476

Group type: EXPERIMENTAL
Intervention: everolimus (EVR) with reduced-exposure calcineurin inhibitor (EVR + rCNI)
Number of subjects: 2037

Group type: COMPARATOR
Intervention: mycophenolate with standard-exposure CNI
Number of subjects: 2037
Study: 27645834

Group type: EXPERIMENTAL
Intervention: CBT-I (Cognitive Behavior Therapy for Insomnia)
Number of subjects: 112

Group type: COMPARATOR
Intervention: WL (Wait-list)
Number of subjects: 112
Study: 26882041

Group type: EXPERIMENTAL
Intervention: Blood pressure-lowering therapy in patients with preserved LVEF (>55%)
Number of subjects: 1849

Group type: EXPERIMENTAL
Intervention: Blood pressure-lowering therapy in patients with intermediate LVEF (45-55%)
Number of subjects: 1849

Group type: EXPERIMENTAL
Intervention: Blood pressure-lowering therapy in patients with reduced LVEF (<45%)
Number of subjects: 1849
Study: 25424952

Group type: EXPERIMENTAL
Intervention: Co-administered qHPV and HAV/HBV vaccine
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Separated doses of qHPV and HAV/HBV vaccine
Number of subjects: 416

Group type: COMPARATOR
Intervention: Both groups post-second dose of qHPV and HAV/HBV
Number of subjects: 416
Study: 22329385

Group type: EXPERIMENTAL
Intervention: Healthy Start intervention (HV+)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cognitive reframing intervention (HV)
Number of subjects: 0
Study: 20080850

Group type: EXPERIMENTAL
Intervention: T(3) therapy (0.8 microg . kg(‐1) bolus; infusion 0.113 microg . kg(‐1) . h(‐1))
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: T(3) therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (5% dextrose)
Number of subjects: 30
Study: 17631211

Group type: EXPERIMENTAL
Intervention: BNP
Number of subjects: 3761

Group type: EXPERIMENTAL
Intervention: NT-proBNP
Number of subjects: 3761

Group type: COMPARATOR
Intervention: ACE inhibition
Number of subjects: 3761
Study: 15290000

Group type: EXPERIMENTAL
Intervention: Duloxetine 80 mg QD
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg BID
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Desipramine 50 mg BID
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 11710819

Group type: EXPERIMENTAL
Intervention: Granisetron 3 mg plus dexamethasone 10 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ondansetron 8 mg plus dexamethasone 10 mg
Number of subjects: 40
Study: 9164214

Group type: EXPERIMENTAL
Intervention: Systemic fluorouracil (5FU)/folinic acid
Number of subjects: 135

Group type: COMPARATOR
Intervention: Symptom control
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Hepatic arterial floxuridine (FUDR)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Systemic chemotherapy
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Hepatic arterial chemotherapy (HAI)
Number of subjects: 135
Study: 7967418

Group type: EXPERIMENTAL
Intervention: NHL-BFM 90 therapy
Number of subjects: 346
Study: 3111821

Group type: EXPERIMENTAL
Intervention: Paedmin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vamin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both nutrition groups
Number of subjects: 0
Study: 1699654

Group type: EXPERIMENTAL
Intervention: 50 micrograms/m2 per day of rhG-CSF
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 100 micrograms/m2 per day of rhG-CSF
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 200 micrograms/m2 per day of rhG-CSF
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: More than 100 micrograms/m2 per day of rhG-CSF
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 400 micrograms/m2 per day of rhG-CSF
Number of subjects: 16
Study: 4397655

Group type: EXPERIMENTAL
Intervention: Oxprenolol
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 31959224

Group type: EXPERIMENTAL
Intervention: Tailored cognitive behavioural therapy (CBT) intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: Supportive listening (SL) intervention
Number of subjects: 60
Study: 31231865

Group type: EXPERIMENTAL
Intervention: 80 mg atorvastatin (ATV) daily for a median of 27 days
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study: 28953118

Group type: EXPERIMENTAL
Intervention: Large Loop Excision of the Transformation Zone (LLETZ)
Number of subjects: 172

Group type: COMPARATOR
Intervention: True Cone Biopsy Electrode Excision (TCBEE)
Number of subjects: 172
Study: 25609033

Group type: EXPERIMENTAL
Intervention: XP Bond adhesive with 15 seconds etching time in G1 (21-35 years)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: XP Bond adhesive with 30 seconds etching time in G1 (21-35 years)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: XP Bond adhesive with 15 seconds etching time in G2 (40-54 years)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: XP Bond adhesive with 30 seconds etching time in G2 (40-54 years)
Number of subjects: 40
Study: 23122836

Group type: EXPERIMENTAL
Intervention: 20% Intralipid (IL) infusion
Number of subjects: 28

Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 28
Study: 21604929

Group type: EXPERIMENTAL
Intervention: Home-based exercise programme
Number of subjects: 30
Study: 19566559

Group type: EXPERIMENTAL
Intervention: Structured antenatal education (two 15‐min sessions)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Normal care (control group)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 100

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 100
Study: 16231165

Group type: EXPERIMENTAL
Intervention: Video presentation before surgery
Number of subjects: 100

Group type: COMPARATOR
Intervention: No video presentation (Control)
Number of subjects: 100
Study: 14715353

Group type: EXPERIMENTAL
Intervention: Helicobacter pylori eradication
Number of subjects: 87
Study: 11711768

Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum 299V (LP299V) in liquid suspension
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 9204357

Group type: EXPERIMENTAL
Intervention: iopentol (Imagopaque 300 mg I/ml)
Number of subjects: 129

Group type: COMPARATOR
Intervention: amidotrizoate (Peritrast 300 mg I/ml)
Number of subjects: 129
Study: 7953013

Group type: EXPERIMENTAL
Intervention: 10 mg of oral haloperidol
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: 30 mg of oral haloperidol
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: 80 mg of oral haloperidol
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Adjunctive lorazepam (for non-responders)
Number of subjects: 47
Study: 3673203

Group type: EXPERIMENTAL
Intervention: Three doses of 3 micrograms given at 0, 1 and 6 months
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Three doses of 3 micrograms given at 0, 1 and 2 months
Number of subjects: 203

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 203
Study: 29720124

Group type: EXPERIMENTAL
Intervention: smalltalk program (group program only or group program with additional home coaching)
Number of subjects: 1226

Group type: COMPARATOR
Intervention: standard/usual care (control)
Number of subjects: 1226
Study: 28520577

Group type: EXPERIMENTAL
Intervention: Sevoflurane-remifentanil (Group SR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sevoflurane-saline (Group SS)
Number of subjects: 0
Study: 26402043

Group type: EXPERIMENTAL
Intervention: Depletion condition (self-regulatory resources reduced)
Number of subjects: 120

Group type: COMPARATOR
Intervention: No-depletion condition (self-regulatory resources intact)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Depletion condition with high trait self-control
Number of subjects: 120
Study: 23664712

Group type: EXPERIMENTAL
Intervention: Antidepressant pharmacotherapy (three different regimens) for 12 weeks
Number of subjects: 96

Group type: COMPARATOR
Intervention: Non-depressed controls
Number of subjects: 96
Study: 21615671

Group type: EXPERIMENTAL
Intervention: muraglitazar (MURA), 5 mg/day
Number of subjects: 27

Group type: COMPARATOR
Intervention: placebo (PLAC)
Number of subjects: 27
Study: 19560327

Group type: EXPERIMENTAL
Intervention: D-camphor-crataegus berry extract combination (Korodin)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 16469981

Group type: EXPERIMENTAL
Intervention: High-isoflavone soy protein isolate (high-iso SPI; 61.7 ± 7.4 mg aglycone isoflavones/d)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Low-isoflavone soy protein isolate (low-iso SPI; 1.64 ± 0.19 mg aglycone isoflavones/d)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Milk protein isolate (MPI)
Number of subjects: 35
Study: 16138726

Group type: EXPERIMENTAL
Intervention: Self‐regulatory care
Number of subjects: 224

Group type: COMPARATOR
Intervention: Routine nursery care (control)
Number of subjects: 224
Study: 11693319

Group type: EXPERIMENTAL
Intervention: H. pylori eradication therapy with standardized 3-month omeprazole treatment
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo with standardized 3-month omeprazole treatment
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Both groups (H. pylori eradication and placebo)
Number of subjects: 151
Study: 9135268

Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Left lateral position
Number of subjects: 24

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 24

Group type: COMPARATOR
Intervention: Right lateral position
Number of subjects: 24
Study: 7968373

Group type: EXPERIMENTAL
Intervention: Alzheimer's disease patients (AD)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control brains
Number of subjects: 5
Study: 3108171

Group type: EXPERIMENTAL
Intervention: Ritanserin (20 mg daily)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Lorazepam (5 mg daily)
Number of subjects: 24
Study: 30137281

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy (cisplatin 100 mg/m2 day 1 and fluorouracil 750 mg/m2/24 hours, days 1-5 with concurrent radiotherapy 40 Gy, 2 Gy/fraction, 5 days a week)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy (cisplatin 100 mg/m2 day 1 and fluorouracil 750 mg/m2/24 hours, days 1-5)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy
Number of subjects: 181

Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy
Number of subjects: 181
Study: 28116581

Group type: EXPERIMENTAL
Intervention: Citalopram (serotonin reuptake inhibitor)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Atomoxetine (noradrenaline reuptake inhibitor)
Number of subjects: 27
Study: 25945865

Group type: EXPERIMENTAL
Intervention: Carvedilol treatment (group A, n = 16)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conventional treatment (group B, n = 20)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (30 healthy children)
Number of subjects: 36
Study: 23637276

Group type: EXPERIMENTAL
Intervention: Topical shellac
Number of subjects: 26

Group type: COMPARATOR
Intervention: 10% povidone-iodine (PVP-I) solution
Number of subjects: 26
Study: 21525157

Group type: EXPERIMENTAL
Intervention: Risedronate 35 mg weekly
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Low-dose transdermal testosterone replacement therapy
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Combination therapy (Risedronate + Testosterone)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77